Long

$ROKU Oversold - Buy the Blood

Oversold - Buy the Blood

This is the most oversold this stock has been since the pandemic market lows of March 2020. I'm expecting a bounce here sometime in the next week. Great company with solid earnings. This selloff is overdone in my opinion. Avg analyst price target is about $408 right now, with vast majority giving it a Buy rating.

Near term target: $275-$300 range possible by year-end

Note: This is NOT investment advice. Educational only.

Triple_Barrel_Capital

Also on:

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.